Research Triangle Park, NC (PRWEB) November 30, 2016 — T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that CEO, John Didsbury, will be presenting cognitive testing and neuroimaging results of a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients at CTAD 2016. Preliminary results of a 26-week open label extension of the main study will also be presented. The oral presentation will take place on Friday, December 9th in San Diego, CA.
A Novel Approach to Alzheimer’s Drug Therapy, Phase 2a Clinical Trial Results of T3D-959 to be Presented by T3D Therapeutics at CTAD
Dec 1, 2016 | News | 0 comments